A combination drug treatment doubled survival time for patients with an aggressive form of colorectal cancer, according to late-stage trial...
Cancer Healthcare
Doctors have developed an artificial intelligence tool that can predict which men with prostate cancer will benefit from a drug...
Pfizer (NYSE:PFE) recently presented groundbreaking findings in cancer research, particularly the first-in-human Phase 1 clinical study of the innovative MesoC2...
Every year, 20 million people globally are diagnosed with cancer.1 Every patient is unique, with hundreds of distinct tumor sub-types,...
Barriers to discussing cancer-related fatigue with healthcare providers remain widespread and, in many areas, more intense now than they were...
Data show continuous clinically significant improvement, with median 13-month and 3-month increases in overall and progression-free survival, respectively, in treatment group...
